198 related articles for article (PubMed ID: 16285354)
1. Pharmacokinetics, pharmacodynamics, safety and tolerability of tigecycline.
Rello J
J Chemother; 2005 Aug; 17 Suppl 1():12-22. PubMed ID: 16285354
[TBL] [Abstract][Full Text] [Related]
2. Pharmacokinetics of tigecycline after single and multiple doses in healthy subjects.
Muralidharan G; Micalizzi M; Speth J; Raible D; Troy S
Antimicrob Agents Chemother; 2005 Jan; 49(1):220-9. PubMed ID: 15616299
[TBL] [Abstract][Full Text] [Related]
3. Tigecycline pharmacokinetics, tolerability, safety, and effect on intestinal microflora in healthy Japanese male subjects.
Yamashita N; Matschke K; Gandhi A; Korth-Bradley J
J Clin Pharmacol; 2014 May; 54(5):513-9. PubMed ID: 24243316
[TBL] [Abstract][Full Text] [Related]
4. Pharmacokinetics and safety of a single intravenous dose of the antibiotic tigecycline in patients with cirrhosis.
Korth-Bradley JM; Baird-Bellaire SJ; Patat AA; Troy SM; Böhmer GM; Gleiter CH; Buecheler R; Morgan MY
J Clin Pharmacol; 2011 Jan; 51(1):93-101. PubMed ID: 20308689
[TBL] [Abstract][Full Text] [Related]
5. Exposure-response analyses of tigecycline tolerability in healthy subjects.
Passarell J; Ludwig E; Liolios K; Meagher AK; Grasela TH; Babinchak T; Ellis-Grosse EJ
Diagn Microbiol Infect Dis; 2009 Oct; 65(2):123-9. PubMed ID: 19748422
[TBL] [Abstract][Full Text] [Related]
6. Absence of an interaction between tigecycline and digoxin in healthy men.
Zimmerman JJ; Harper DM; Matschke K; Speth JL; Raible DG; Fruncillo RJ
Pharmacotherapy; 2007 Jun; 27(6):835-44. PubMed ID: 17542766
[TBL] [Abstract][Full Text] [Related]
7. A review of tigecycline.
French GL
J Chemother; 2008 Oct; 20 Suppl 1():3-11. PubMed ID: 19036669
[TBL] [Abstract][Full Text] [Related]
8. Steady-state serum and intrapulmonary pharmacokinetics and pharmacodynamics of tigecycline.
Conte JE; Golden JA; Kelly MG; Zurlinden E
Int J Antimicrob Agents; 2005 Jun; 25(6):523-9. PubMed ID: 15885987
[TBL] [Abstract][Full Text] [Related]
9. Pharmacokinetic/pharmacodynamic profile for tigecycline-a new glycylcycline antimicrobial agent.
Meagher AK; Ambrose PG; Grasela TH; Ellis-Grosse EJ
Diagn Microbiol Infect Dis; 2005 Jul; 52(3):165-71. PubMed ID: 16105560
[TBL] [Abstract][Full Text] [Related]
10. Results of a multicenter, randomized, open-label efficacy and safety study of two doses of tigecycline for complicated skin and skin-structure infections in hospitalized patients.
Postier RG; Green SL; Klein SR; Ellis-Grosse EJ; Loh E;
Clin Ther; 2004 May; 26(5):704-14. PubMed ID: 15220014
[TBL] [Abstract][Full Text] [Related]
11. Metabolism, excretion, and pharmacokinetics of [14C]tigecycline, a first-in-class glycylcycline antibiotic, after intravenous infusion to healthy male subjects.
Hoffmann M; DeMaio W; Jordan RA; Talaat R; Harper D; Speth J; Scatina J
Drug Metab Dispos; 2007 Sep; 35(9):1543-53. PubMed ID: 17537869
[TBL] [Abstract][Full Text] [Related]
12. The pharmacokinetic and pharmacodynamic profile of tigecycline.
Meagher AK; Ambrose PG; Grasela TH; Ellis-Grosse EJ
Clin Infect Dis; 2005 Sep; 41 Suppl 5():S333-40. PubMed ID: 16080071
[TBL] [Abstract][Full Text] [Related]
13. Tigecycline: a single antibiotic for polymicrobial infections.
Pankey GA; Steele RW
Pediatr Infect Dis J; 2007 Jan; 26(1):77-8. PubMed ID: 17195711
[No Abstract] [Full Text] [Related]
14. Efficacy and safety of tigecycline monotherapy compared with vancomycin plus aztreonam in patients with complicated skin and skin structure infections: Results from a phase 3, randomized, double-blind trial.
Sacchidanand S; Penn RL; Embil JM; Campos ME; Curcio D; Ellis-Grosse E; Loh E; Rose G
Int J Infect Dis; 2005 Sep; 9(5):251-61. PubMed ID: 16099700
[TBL] [Abstract][Full Text] [Related]
15. Clinical pharmacokinetics and pharmacodynamics of tigecycline.
Barbour A; Schmidt S; Ma B; Schiefelbein L; Rand KH; Burkhardt O; Derendorf H
Clin Pharmacokinet; 2009; 48(9):575-84. PubMed ID: 19725592
[TBL] [Abstract][Full Text] [Related]
16. Tigecycline : a critical safety review.
Kaewpoowat Q; Ostrosky-Zeichner L
Expert Opin Drug Saf; 2015 Feb; 14(2):335-42. PubMed ID: 25539800
[TBL] [Abstract][Full Text] [Related]
17. A Phase 3, open-label, non-comparative study of tigecycline in the treatment of patients with selected serious infections due to resistant Gram-negative organisms including Enterobacter species, Acinetobacter baumannii and Klebsiella pneumoniae.
Vasilev K; Reshedko G; Orasan R; Sanchez M; Teras J; Babinchak T; Dukart G; Cooper A; Dartois N; Gandjini H; Orrico R; Ellis-Grosse E;
J Antimicrob Chemother; 2008 Sep; 62 Suppl 1():i29-40. PubMed ID: 18684704
[TBL] [Abstract][Full Text] [Related]
18. Serum and urine pharmacokinetics of tigecycline in obese class III and normal weight adults.
Pai MP
J Antimicrob Chemother; 2014 Jan; 69(1):190-9. PubMed ID: 23883872
[TBL] [Abstract][Full Text] [Related]
19. Tigecycline: an expanded broad-spectrum intravenous antibiotic. Preface and summary.
Felmingham D
J Chemother; 2005 Aug; 17 Suppl 1():3-4. PubMed ID: 16429623
[No Abstract] [Full Text] [Related]
20. Safety and efficacy of intravenous tigecycline in treatment of community-acquired pneumonia: results from a double-blind randomized phase 3 comparison study with levofloxacin.
Bergallo C; Jasovich A; Teglia O; Oliva ME; Lentnek A; de Wouters L; Zlocowski JC; Dukart G; Cooper A; Mallick R;
Diagn Microbiol Infect Dis; 2009 Jan; 63(1):52-61. PubMed ID: 18990531
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
